Авторы

  • Махмудова А.Д.
  • Курязов А.М.
  • Бобоев К.Т.
  • Бергер И.В.

Ключевые слова:

миелопролиферативные заболевания, мутации генов, диагностика.

Библиографические ссылки

Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных новообразований. Клиническая онкогематология. 2016;9(3):314–25.

Кесаева Л.А., Мисюрина Е.Н., Марьин Д.С.и др. Экспрессия гена BCR-ABL1 у пациентов с хроническими миелопролиферативными заболеваниями с признаками прогрессирования. Клиническая онкогематология. 2018; 11(4): 354 –9.

Силютина А.А., Гин И.И., Матюхина Н.М. и др. Модели миелофиброза (обзор литературы и собственные данные). Клиническая онкогематология. 2017;10(1):75–84.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. PMID: 25116092.

Michiels JJ, Tevet M, Trifa A, Niculescu-Mizil E, Lupu A, Vladareanu AM, Bumbea H, Ilea A, Dobrea C, Georgescu D, Patrinoiu O, Popescu M, Murat M, Dragan C, Mihai F, Zurac S, Angelescu S, Iova A, Popa A, Gogulescu R, Popov V. 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications. Maedica (Bucur). 2016 Mar;11(1):5-25. PMID: 28465746; PMCID: PMC5394501.

Lyu XD, Li YW, Guo Z, Xin YP, Hu JY, Fan RH, Song YP. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms]. Zhonghua Nei Ke Za Zhi. 2020 Jan 1;59(1):35-39. Chinese. doi: 10.3760/cma.j.issn.0578-1426.2020.01.006. PMID: 31887834.

Kim Y, Park J, Jo I, Lee GD, Kim J, Kwon A, Choi H, Jang W, Chae H, Han K, Eom KS, Cho BS, Lee SE, Yang J, Shin SH, Kim H, Ko YH, Park H, Jin JY, Lee S, Jekarl DW, Yahng SA, Kim M. Genetic-pathologic characterization of myeloproliferative neoplasms. Exp Mol Med. 2016 Jul 22;48(7):e247. doi: 10.1038/emm.2016.55. PMID: 27444979; PMCID: PMC4973314.

Ojeda MJ, Bragós IM, Calvo KL, Williams GM, Carbonell MM, Pratti AF. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology. 2018 May;23(4):208-211. doi: 10.1080/10245332. 2017.1385891. Epub 2017 Oct 9. PMID: 28990497.

Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014 Jun 12;123(24):3714-9. doi: 10.1182/blood-2014-03-530865. Epub 2014 Apr 30. PMID: 24786775.

Greenfield G, McMullin MF, Mills K. Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol. 2021 Jun 30;14(1):103. doi: 10.1186/s13045-021-01116-z. PMID: 34193229; PMCID: PMC8246678.

Rolles B, Mullally A. Molecular Pathogenesis of Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2022 Dec;17(6):319-329. doi: 10.1007 /s11899-022-00685-1. Epub 2022 Nov 7. PMID: 36336766.

Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, Barbui T, Arber DA, Tefferi A. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 Jan;98(1):166-179. doi: 10.1002/ajh.26751. Epub 2022 Oct 14. Erratum in: Am J Hematol. 2023 Jan 4: PMID: 3620 0127.

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A. Uj lehetoség a krónikus myeloproliferativ betegségek diagnosztikájában--a JAK2 mutaći6ókimutatása [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Orv Hetil. 2006 Nov 12; 147(45): 2175-9. Hungarian. PMID: 17 402211.

Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombo-cythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol. 2009 May;7(5):334-42. PMID: 19521323.

Morsia E, Torre E, Poloni A, Olivieri A, Rupoli S. Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications. Int J Mol Sci. 2022 Apr 20;23(9):4573. doi: 10.3390/ijms23094573. PMID: 35562964; PMCID: PMC9100530.

Dunbar A, Nazir A, Levine R. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Curr Protoc Pharmacol. 2017 Jun 22;77:14.40.1-14.40.19. doi: 10.1002/cpph.23. PMID: 28640953; PMCID: PMC6352313.

Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. PMID: 28028029.

Saeidi K. Myeloproliferative neoplasms: Current molecular biology and genetics. Crit Rev Oncol Hematol. 2016 Feb;98:375-89. doi: 10.1016/j.critrevonc.2015.11.004. Epub 2015 Nov 28. PMID: 26697989.

Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. BMC Cancer. 2019 Jun 17;19(1):590. doi: 10.1186/s12885-019-5764-4. PMID: 31208359; PMCID: PMC6580484.

Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 Apr 20;141(16):1909-1921. doi: 10.1182/blood.2022017578. PMID: 36347013.

Tremblay D, Yacoub A, Hoffman R. Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications. Hematol Oncol Clin North Am. 2021 Apr;35(2):159-176. doi: 10.1016/j.hoc.2020.12.001. Epub 2021 Jan 26. PMID: 33641861; PMCID: PMC8669599.